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Summary  
The therapeutic potential of mesenchymal stromal cells (MSC) in the treatment of liver 
fibrosis is predominantly based on their immunosuppressive properties, and their ability to 
secrete various trophic factors. This potential has been investigated in clinical and pre-clinical 
studies. Although the therapeutic mechanisms of MSC transplantation are still not fully 
characterized, accumulating evidence has revealed that various trophic factors secreted by 
MSC play key therapeutic roles in regeneration by alleviating inflammation, apoptosis, and 
fibrosis as well as stimulating angiogenesis and tissue regeneration in damaged liver. In this 
review, we summarize the safety, efficacy, potential transplantation routes and therapeutic 
effects of MSC in patients with liver fibrosis. We also discuss some of the key strategies to 
enhance the functionality of MSC, which include sorting and/or priming with factors such as 
cytokines, and also genetic engineering of MSC. 
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Introduction  
Liver disease is a major cause of mortality and morbidity that is rising globally [1, 2]. There 
remain many inflammatory liver conditions for which treatments are not effective and often 
such patients will progress to end-stage liver disease and require liver transplantation. To 
prevent progression to end-stage liver disease and also to treat those with advanced fibrosis 
mesenchymal stromal cell (MSC) therapies have been considered and shown to have 
potential in such liver diseases [3-5].  
MSC have been shown to have beneficial effects in a range of clinical settings including heart 
failure [6], lung injury [7, 8], graft versus host diseases [9] and stroke [10], as well as being 
reported to ameliorate liver injury in the setting of both acute and chronic liver damage [11, 
12]. The pleiotropic effects of MSC represent a potential advantage over pharmacological 
therapies and principally focus on their ability to modulate different components of the 
immune system either directly or by the release of paracrine factors. In addition to these 
immunomodulatory effects, MSC have been shown to reduce liver injury by ameliorating 
oxidative stress through release of antioxidants [12] and also through anti-fibrotic effects [3, 
5]. In addition, MSC have been reported to have an ability to differentiate to hepatocyte-like 
cells which may show promise in augmenting liver regeneration [13, 14]. These encouraging 
pre-clinical data have resulted in many clinical trials [15, 16], and it is therefore timely to 
review the data underpinning these effects and also address the important remaining scientific 
questions so as to establish MSC therapy for patients with liver disease.   
 
MSC: Definition, Biology and Tissue Origins  
MSC were initially described in the 1968 by Friedenstein [17], and are a subtype of adult 
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fibroblast-like cells that have the capacity of self-renewal with high proliferative ability. They 
can undergo tri-lineage differentiation both in vivo and in vitro down connective tissue 
lineages to become osteoblasts, chondrocytes and adipocytes.  
MSC are plastic adherent cells originally identified and isolated from bone marrow but due to 
their limited number (0.01 to 0.001% of total bone marrow cells) [18] and invasive nature of 
their isolation from bone marrow, researchers explored alternative sources. Several studies 
have reported the successful isolation of MSC from different tissues with similar in vitro 
properties, including synovial membrane [19], adipose tissue (AT) [20], umbilical cord blood 
(UCB) [21], amniotic fluid (AF) [22] and placenta [23]. Umbilical cord tissue (UC) has been 
a particularly promising source of MSC - cells can be isolated from several compartments 
within UC including umbilical vein, umbilical arteries, umbilical cord perivascular tissue, 
Wharton’s jelly (WJ) and sub-amniotic tissue. Furthermore, MSC isolated from UC tissue are 
believed to be more primitive than other cells isolated from other tissues and are found in 
higher numbers, ensuring this source is gaining prominence. Notably, MSCs from different 
sources display similar expression profile of MSCs surface markers and morphological 
features in culture, yet they have different levels of tri-lineage differentiation potential [24]. 
In addition, further differences have been related to the culture conditions, especially in the 
isolation procedure and culturing protocols, as well as the experiment protocol used [25]. 
Whereas, direct comparisons of MSCs from different sources have been shown to share 
similar biological properties [26-28], other authors demonstrated differences in 
immunomodulatory properties between BM-MSCs, UC-MSCs, and AT-MSCs [29, 30]. In 
addition, umbilical cord MSCs exhibit a higher proliferative capacity in comparison to MSCs 
populations obtained from other sources [24].   
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MSC from differing sources such as AT, UCB, and BM were found to express a similar 
pattern of surface antigens [31], although there was variation in respect to their differentiation 
potential, morphology and proliferation rate [32]. Moreover, several studies have 
demonstrated that BM MSC have higher expression of pluripotency genes such as Oct-4, 
Nanog, and Sox-2 than those isolated from WJ and AT [33]. 
 
Potential mechanisms of action of MSC in liver disease 
Mechanism of immunomodulation by MSC 
MSC can modulate and repair injured tissue by modulating injurious immune responses 
through a range of mechanisms including direct cell to cell interaction or remotely by 
secretion of paracrine factors (Fig. 1) [34]. Of note, MSC have reduced immunogenicity due 
to a lack expression of class II major histocompatibility (MHC) antigens when unprimed and 
do not express many of the molecules required for immune recognition such as CD80, 
CD86n and CD40 [35].  
 
Immunomodulatory effect of MSC on adaptive immunity 
MSC can inhibit the proliferation of T cells in vitro by either secretion of soluble factors or 
by direct interaction with T-lymphocytes (Fig. 2) [36]. Several different molecules secreted 
by MSC have been reported to have an immunomodulatory effect on T-cell activities, 
including transforming growth factor β (TGF-β), hepatocyte growth factor (HGF) [36], 
prostaglandin E2 (PGE2) [37], and indoleamine 2,3-dioxygenase (IDO) [38]. Notably, the 
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production of these immunomodulatory molecules differs according to the source of MSC, 
for example, WJ-MSC produce higher amounts of TGF-β than BM-MSC [39].  
 
The inflammatory environment is known to have an essential role during the interaction 
between MSC and T cells, for example, the immunosuppressive capacity of MSC is induced 
by treatment with combination of cytokines (IFN-γ, IL-1α, TNF-α, and IL-1β) [40]. These 
cytokines can enhance some chemokines and other immune cells to easily contact the MSC 
and mediate the immune reactions. Another mechanism by which MSC can suppress the 
proliferation of T cells is via secretion of nitric oxide (NO) which causes inhibition of STAT5 
pathways [41]. Another study demonstrated that MSC can secrete matrix metalloproteinases 
(MMP), such as MMP-2 and MMP-9, which suppress T cell activation by cleaving surface 
CD25 from T cells [42].  
 
MSC have also been shown to promote the generation and development of regulatory T cells 
(Tregs), which can positively influence balance of immune damage during tissue injury [43].  
The induction of CD4+ CD25+ FOXP3+ Treg was mediated by secretion of TGF-β [44] and 
is accompanied by an inhibition of the proliferation and differentiation of Th1 and Th17 
helper T cells which can further trigger activation of regulatory T cells. This mechanism was 
associated with an increased production of IL-10 by MSC [45].  
 
MSC can also inhibit the proliferation of B cells, and reduce their production of 
immunoglobulin. Glennie et al used CD40 and IL-4 to increase the proliferation rate of 
murine B cells and demonstrated that subsequent co-culture with MSC significantly inhibited 
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their proliferation [46]. In addition, MSC resulted in a significant stimulation in 
immunoglobulin production after co-culture of B cells in trans-well experiment [47]. MSC 
may also alter surface expression of chemokine receptors on B cells; co-culture with MSC in 
1:1 ratio resulted in a significant reduction of expression of CXCR4, CCR7 and CXCR5 on B 
cells [48]. CXCR4 was found to significantly reduced even with 1:10 ratio when cultured 
with MSC, suggesting that MSC can specifically target CXCR4 which has a role in homing 
and fate of MSC [49].   
 
Natural killer cells (NK) represent a critical component of the immune response against viral 
infections and tumor cells [50] - Sotiropoulou et al demonstrated that MSC reduced IL-15 
secretion from IL-2 induced NK cells. This reduction was presumed to be due to either cell-
to-cell interaction or release of soluble factors such as PGE2 and TGF-β [35]. In addition, 
another group reported that MSC can suppress NK cells after stimulation with IL-5 [50]. In 
models of acute liver injury MSC ameliorated hepatotoxicity of NKT cell in an indoleamine 
2,3-dioxygenase (IDO) dependent manner, by reducing the number of IL-17 cells and 
stimulation of FOXP3 and IL-10 resulting from increased numbers of NK Treg in the injured 
liver [51].  
 
Immunomodulatory effect of MSC in innate immunity 
Macrophages can be classified into classical pro-inflammatory macrophages (M1) or 
alternative macrophages (M2) that secret anti-inflammatory cytokines (Fig. 2) [52]. MSC 
have been reported to trigger polarization of M1 toward M2 both in vivo and in vitro. This 
polarization is driven by the ability of MSC to secrete soluble factors such as interleukin (IL)-
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10 and IL-1Ra which have been shown to attenuate liver injury by promoting number of M2 
macrophages [53]. In addition to the IL-10 mediated ability of MSC to promote switching 
phenotype of macrophages from M1 to M2, MSC can also help to promote survival of 
monocytes through upregulation of CCL18, which was found to indirectly mediate ability of 
MSCs to induce Tregs formation [44] as demonstrated in animal models of sepsis and colitis 
[54]. In this study murine adipose derived MSC significantly increased the proportion of M2 
like cells by increased production of IL10 and arginase1 activities [54].  
MSC can also regulate, and interact with, dendritic cell function (DC) by blocking 
differentiation of antigen presenting cells (APC) to monocytes and decreasing their 
expression of anti-inflammatory molecules such as IL12, TNF-α, and IFN-γ, whilst also 
enhancing their secretion of IL-10 which may induce regulatory T cell numbers (Fig. 2) [55]. 
Notably, WJ-MSC can also inhibit the differentiation of monocytes to mature dendritic cells 
when cultured with CD14+ monocytes, indicating an indirect effect of WJ-MSC on the 
allogeneic response of T cells [56]. There is now therefore a greater recognition of the 
importance of the microenvironment on the immunomodulatory capacity of MSC [40], 
prompting a need for a better understanding of the microenvironment associated with specific 
diseases so as to develop more effective therapeutic efficacy of MSC.  
 
Anti-fibrotic activities of MSC 
Inflammation and fibrosis have a very close relationship in liver disease. In response to liver 
injury, pro-fibrotic factors such as TGF‐β, platelet‐derived growth factor (PDGF), IL-13 and 
IL-4, which are secreted by resident or infiltrating immune cells, play important roles in the 
activation and proliferation of hepatic stellate cells (HSC), which are important cells for the 
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production of ECM in the liver [57-60]. Therefore, the anti-fibrotic activities of MSC can be 
distinguish the direct or indirect effects on HSC. The indirect anti-fibrotic effects on HSC are 
achieved by MSC controlling immune cells and sequentially inhibiting the activity of HSC, 
whereas the direct anti-fibrosis effects on HSC are mediated by MSC inhibiting the activity 
of HSC. 
As the indirect anti-fibrotic effects of MSC on HSC, MSC can regulate the activities of HSC 
by modulating immune cell activity mentioned above. MSC can migrate towards injured sites 
of inflammatory reaction where they are exposed to inflammatory cytokines such as IFN-γ 
and IL-1β [61, 62]. These MSC secrete various soluble mediators (e.g. NO, PGE2, IDO, IL-6, 
IL-10, and HLA-G), thus resulting in the suppression of the proliferation and activation of a 
variety of immune cells as well as the induction of Treg cells [63]. Thus, suppression of 
immune cell activities by MSC can also reduce fibrogenic processes and ameliorate ECM 
accumulation in liver disease. In particular, macrophages play a central role in both fibrosis 
and fibrotic resolution in the liver [64, 65] - during hepatic fibrogenesis, pro-inflammatory 
M1 macrophages located near the activated hepatic myofibroblasts secrete pro-fibrogenic 
factors such as TGF-β, PDGF, and CCL2. This secretion leads to increased fibrogenic 
responses of the myofibroblasts through the promotion of their activation, proliferation, and 
chemotaxis [64, 66]. However, macrophages co-cultured with MSC are polarized into anti-
inflammatory M2 states, which show higher phagocytic activity through increased expression 
of IL-10 and decreased expression of tumor necrosis factor (TNF)-α and IL-12p40 [67, 68]. 
These results suggest that MSC can induce changes in the cytokine profile of activated 
macrophages promoting resolution of fibrosis. PGE2 has also been reported as a major 
immunomodulatory molecule when MSC are co-cultured with macrophages [69-71].  
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As the direct anti-fibrotic effects of MSC on HSC, MSC can inhibit proliferation and ECM 
production potential of HSC and also induce apoptosis of HSC. MSC can secrete IL-10, HGF, 
TGF-β3 and TNF-α, inhibit the proliferation of HSC, and decrease ECM synthesis [72, 73]. 
TGF-β3 and HGF induce G0/G1 cell cycle arrest of HSC by upregulating p21Cip1 and p27Kip1 
and downregulating cyclin D1, which leads to HSC growth inhibition [73]. Similarly, 
neutralization of secretion of TNF-α and IL-10 from MSC inhibits activated HSC 
proliferation and ECM synthesis [72]. Moreover, MSC-derived HGF can also accelerate the 
rate of HSC apoptosis [72] and MSC cultured with HGF improve serum albumin level and 
reduce liver fibrosis in rats [74]. The Notch pathway is activated during direct co-culture of 
MSC and HSC through a cell–cell contact mode and results in significant suppression of the 
proliferation and α-SMA expression of HSC [75]. In liver fibrosis, activated HSC can express 
the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2, specific inhibitors of MMP 
[76], whereas MSC have been reported to increase the expression of MMP (e.g. MMP-2, -9, -
13 and -14) [77-79] or decrease TIMP-1 expression [80], which are generally associated with 
fibrosis resolution in experimental models. 
 
Hepatocyte-like differentiation of MSC 
Since hepatocytes have been reported to improve liver function and mitigate fibrosis in 
preclinical and clinical studies, hepatocyte transplantation has been considered an alternative 
therapy to replace liver transplantation. Several factors influence the hepatic differentiation of 
MSC. It has been reported that the treatment of MSC with a combination of several growth 
factors, cytokine, and chemical compounds (i.e., HGF, fibroblast growth factor [FGF]-2/-4, 
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epidermal growth factor [EGF], oncostatin M [OSM], leukemia inhibitory factor [LIF], 
dexamethasone [Dex], insulin-transferrin-selenium [ITS], and/or nicotinamide [NTA]) 
increases the expression of hepatocyte markers such as HNF-3β, GATA4, CK19, 
transthyretin, α-fetoprotein, albumin, and CK18 [81]. In addition, when MSC are co-cultured 
with liver cells [82] or grown by pellet culture [83], they can be differentiated into 
hepatocyte-like cells. The differentiation of MSC into hepatocytes has been reported in rats 
[84], mice [85], sheep [86] and humans [87]. Moreover, hepatic stem/progenitor cells isolated 
from the adult human liver have been reported to be much better at being able to differentiate 
into hepatocytes when compared with MSC isolated from other tissues than liver [88]. 
Several groups have also reported that MSC differentiated into hepatocytes can help improve 
liver function and histopathologic grade, although they are less effective than adult 
hepatocytes [89]. There still remains uncertainty in the literature about the characterisation of 
MSC-derived hepatocytes which requires further evaluation, and indeed it is unclear if this 
will be a major means by which MSC are utilised. 
 
Clinical trials using MSC in liver disease 
Many clinical studies have been conducted on the treatment of liver disease using MSC, 
focusing on clinical trial design, cell sources, injection route, patient groups, and efficacy of 
therapies [15, 16, 90-104]. Based on these viewpoints, we addressed 17 articles to summarize 
MSC-based therapy for liver disease from 2007 to July 15, 2017 (Table 1). With regard to 
study design for the treatment of liver disease using MSC, there was one case series, six case 
control studies, five cohort studies, and five randomized clinical trials (RCTs) (Table 1). 
Cohort and case control studies have been performed in the early clinical trials [15, 16, 90-92, 
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94, 96-100, 104], and RCT studies seem to be mainly conducted recently to evaluate the 
efficacy of MSC [93, 95, 101-103]. In the reported studies, a marked heterogeneity was found 
in injected cell dosage, stem cell source, graft type, injection route, and study design, but 
significant adverse effects were not reported in the included studies. The diseases of the 
patients included acute-on-chronic liver failure (ACLF), liver failure including cirrhosis due 
to alcohol, HBV, or HCV, and primary biliary cholangitis. A total of 688 patients were 
enrolled in the clinical studies, with a range of four patients in the case series design [94] to 
158 patients in the case control design [99]. In the clinical studies [99], BM-derived MSC 
(BM-MSC) were used in 14 studies and UC-MSC were used in the remaining three studies. 
In five studies allogenic MSC were used to treat liver disease; two were derived from the BM, 
and three were from UC [15, 16, 96, 100, 102]. Moreover, autologous BM-derived 
hepatocytes were reported to improve Child-Pugh score, MELD score, fatigue scale, and 
performance status over the controls, although no comparison was made with any 
undifferentiated MSC transplantation groups [97]. However, in recent animal studies, it has 
been reported that undifferentiated MSC can more effectively improve liver function than 
MSC differentiated into hepatocytes [89]. Jang et al. analyzed the liver function improvement 
after repeated MSC injections at 4 and 8 weeks [91]. In pilot studies, hepatic fibrosis was 
found to be ameliorated or reduced in six of 11 patients (54.5%) and the Child score 
improved in ten patients (90.9%) [91]. However, in the inter-group comparison (one-time 
injection versus two-time injection), two-time BM-MSC transplantation was not found to 
improve fibrosis over a single transplantation [101]. When three studies using two injection 
routes were analyzed separately [92, 97, 104], the peripheral vein (PV) was found to be most 
commonly used as a transplantation route in 11 cases; the hepatic artery (HA) was used in 
four cases, intra-splenic (IS) injection was used in three cases, intrahepatic (IH) injection in 
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one case, and portal vein in one case. There was no difference in the efficacy of MSC based 
on the route of administration (PV, IS, portal vein or IH) [92, 97, 104] and in the incidence of 
HCC or mortality in hepatic failure patients with hepatitis B between the autologous MSC-
infused and the control groups [99]. In an efficacy analysis after MSC transplantation, 15 
studies reported benefits of using MSC, but two did not.  
Taken together, the results of all these studies can be summarized to say that MSC treatments 
for patients with liver disease are safe and may improve liver function, although robust 
randomised clinical studies are required to gain confidence with regard to the clinical efficacy 
of MSC. However, to improve the efficacy of MSC therapy for liver disease, pre-clinical and 
clinical studies are necessary to standardize the best delivery route of MSC, to optimize the 
sufficient number of MSC, and to elongate the survival duration of engrafted MSC. 
Furthermore, in order to understand the therapeutic mechanism and fate of MSC more clearly, 
it is required to develop a specific biomarker with low toxicity so that the transplanted MSC 
can be accurately tracked. 
 
Future perspectives  
Whilst conventional unmanipulated MSC have been the mainstay of therapeutic studies thus 
far there have been extensive efforts to try and enhance their efficacy. This section will 
review some of the key strategies which include sorting MSC to enrich for greater 
functionality, priming of MSC with factors such as cytokines and finally genetic engineering 
of cells (Fig. 3). The main driver for these approaches is to enhance efficacy and/or organ 
homing although there is also often a need to create/protect intellectual property so as to 
generate a viable business model. The challenge therefore is to balance the additional costs 
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and potential logistical/safety concerns associated with such perturbations against 
improvements in efficacy. 
 
MSC enrichment 
MSC represent heterogeneous populations of cells, therefore, sorting approaches are highly 
considered to achieve homogenous populations of MSC, resulting in enriched subsets which 
could crucially produce various selected populations with different therapeutic functions and 
open new strategies for the modification of MSC for more beneficial effects.  
MSC are phenotypically diverse both morphologically and functionally and thus sorting cells 
based on marker expression may allow for the selection of cells with greater efficacy. This 
does require definition of which function is being focused on, and often markers of stemness 
or proliferation are reported, whereas immunomodulatory action may be the most important. 
Sorting of cells for pre-clinical studies is relatively straightforward and can use a range of 
modalities including flow cell sorting which should result in high purity yields. It is more 
challenging however when such approaches are attempted in clinical practice as they need to 
adhere more closely to good manufacturing practice (GMP) which can restrict the modality 
used. Clinically approved modalities such as the CliniMACS are clinically accredited but 
may not result in high purities of rare populations and thus the use of GMP fluorescence cell 
sorting analysis is encouraging. 
CD146+ is expressed on various cells types including endothelia cells [24] and can contribute 
to biological functions such as cell migration, proliferation and differentiation [105, 106]. 
CD146 expression is correlated with cellular senescence of MSC and markedly affects the 
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proliferation, differentiation, and stemness of hUCB-MSC. Sorted CD146+ MSC have 
delayed cellular senescence which is mediated by regulation of Bmi-1, id1, and Twist1 
expression, which can regulate the cellular senescence process [107]. This suggested that 
CD146+ could be a novel marker responsible for control of senescence of MSCs and hence 
improve the therapeutic efficacy of MSCs. 
In a recent study, sorting MSC sub-populations based on CD73+ expression has demonstrated 
greater self-renewal and differentiation properties [108]. These sorted cells (CD73+) 
exhibited high levels of colony forming unit ability in contrast with an absence observed with 
CD73- cells.  
Another study has characterized populations of MSC using several markers, including 
CD271+, known as nerve growth factor receptor and proposed as a marker of BM stromal 
cells, adhesion molecule (CD56), and MSCA-1+ (mesenchymal stem cell antigen-1) [109]. 
Sorted dual-positive MSCA-1+ and CD56+ MSC were reported to have 2-4 greater clonal 
efficiency than MSCA-1+ CD56-. However, MSCA-1+ CD56- were shown to have potential 
ability to differentiate into adipocytes, whereas MSCA-1+ CD56+ were restricted to 
chondrogenic and pancreatic like cells differentiation. Similarly, other reports indicate that 
enrichment of synovium-derived-MSC using CD271 in combination with THY-1 (CD90) 
results in greater chondrogenic differentiation ability and colony forming potential in the 
CFU-F assay compared to CD271+ CD90+ BM-MSC. Thus, this combination could be a good 
candidate for the isolation of MSC from different tissue sources for cartilage regeneration 
[110]. 
Sherman et al. [111] have proposed aldehyde dehydrogenase (ALDH) as a marker for MSC 
which defines an enhanced ability to contribute to revascularization. MSC isolated from 
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human bone marrow and purified into ALDHhi and ALDHlo populations had identical 
expression of MSC surface makers and ability to differentiate into adipocytes, osteoblasts, 
and chondroblasts in vitro. Notably though conditioned medium from ALDHhi MSC was 
shown to promote endothelial cell expansion in vitro and enhance recruitment of endogenous 
vascular cells after subcutaneously implanted in NOD/SCID mice, which was mediated by 
up-regulation of lectin [111].   
Positive selection on the basis of expression of the Stro-1 specific marker has also been 
proposed and such MSC are enriched with respect to CFU-F progenitors [112]. Stro-1+ 
expanded MSC were reported to have better migratory capacity in various tissues when 
compare to Stro-1- [113]. Other research groups were able to increase expression of cytokines 
related cardiovascular which can be mediated through using Stro-1+ enriched MSC [114].  
Expression of CD200 has also been used to purify MSC [115], with its expression inhibiting 
osteoclast formation via inhibition of RANKL signalling pathways, which consequently 
reduce expression of osteoclast associated genes such as tartrate resistance acid phosphatase 
(TRAP) and nuclear factor of activated T cells cytoplasmic 1 (NFARC1) [116]. Another 
study has clearly shown that CD200+ BM-MSC can modulate the immune response of 
macrophages by inhibition of TNF-α secretion when compared to CD200low BM-MSC [117]. 
Consisting with its role in immunomodulation, MSC have been identified to drive the 
expression of CD200 in T cell subsets following co-culture with MSC [118]. This 
upregulation was reported in both CD4+ and CD8+ T lymphocyte.  
More recently, CD362+ (Syndecan-2) marker has been identified as a novel marker to select a 
homogeneous population of MSC with enhanced immunomodulatory properties (patent 
number WO 20131177661 A1). This marker has recently investigated for its ability to reduce 
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immunogenicity and enhance the immunomodulatory ability in liver inflammation [119, 
120]. Syndecan-2 found to be expressed in hematopoietic cells and myeloid cells [121]. And 
functionally reported to upregulate upon T cell activation and play significance role in CD3 
downregulation through degradation of T-cell receptor (TCR) [122]. These findings strongly 
suggest that enrichment of syndecan-2 expression in MSC could play an essential role in 
immune modulation in injured tissue.  
The potential benefits of the various markers that have been used to select/enrich MSC are 
detailed in Table 2.  
 
MSC priming 
As with selection of MSC, priming of cells before use is intended to enhance their biological 
properties for whichever clinical indication is being considered (Table 3). This may include 
improvements in MSC immunomodulatory effects, homing to injured organs and/or greater 
expansion of cells. 
 
Enhancing immunomodulatory properties of MSC 
Pre-treatment of MSC with the pro-inflammatory cytokines IL-1β, IL-23 and IL-6 for 96 
hours [123] was found to enhance secretion of TGF-β and reduce production of IL-4 by 
MSC, although notably no changes were reported in production of IFN-γ and TNF-α. In 
addition, cytokine-treated MSC exhibited superior multi-lineage differentiation capacity 
compared to untreated MSC, with no associated changes in their morphology. IL-1 appears to 
  
19 
 
be important for pre-conditioning of MSC, as combined treatment with IL-1α and IL-1β 
increases production of granulocyte-colony stimulating factor (G-CSF) and secretion of anti-
inflammatory mediators such as IL-10. Moreover, microglial cells incubated with conditioned 
medium from IL-1 primed MSC increase expression of anti-inflammatory cytokines such as 
IL10 and decrease secretion of pro-inflammatory cytokines as reported in TNF-α and IL-6 
[124].   
Duijvestein et al. [125] showed that stimulation MSC with IFN-γ enhanced the anti-
inflammatory response of MCS in experiment colitis animal model. In addition, IFN-γ 
primed MSC exhibit a significant reduction in TNF-α and IL-6 in colon homogenates, while 
normal MSC had no effect. In the same model, activation of MSC with IFN-γ further promote 
the immunomodulation via enhance production of IL-17 and IL-4, which therefore inhibit the 
Th1 and reduce T cell activation [125]. Under similar conditions, pre-stimulation of BM-
MSC with IFN-γ and TNF-α stimulate production of IL-6, HGF, TGF-β [126]. More 
interestingly, an in vivo GVHD model, administration of MSC pre-treated with IFN-γ have 
the capability to enhance survival rates of mice with GVHD, resulted in 100% survival [127]. 
More recently, data from de Witte and colleagues have demonstrated that pre-treatment of 
UC-MSC with different treatments such as TGF-β, IFN-γ, IFN-β or in combinations (TGF-β, 
IFN-γ and retinoic acid) suppress expression of CD107a on NK cells, enhancing MSC 
immunomodulation. In addition, MSC treated with IFN-γ and the multiple cytokine 
combination were found to significantly upregulate IDO activities which subsequently 
suppressed CD4 and CD8 proliferation when compare to untreated MSC. Notably, following 
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infusion into mice injured with a single dose of CCl4, a higher percentage of TGF-β treated 
MSC homed to the injured liver (25%) compared with untreated MSC (13%) [119].  
In another liver injury studies, IL-7 treated MSC had a superior therapeutic effect on liver 
injury mediated in part through increased activation of iNOS. IL-17 down-regulates gene 
expression of ARE/poly(U)-binding/ degradation factor 1 (AUF-1) in MSC which is a protein 
known to regulate immune related molecules [128] and has a key role in regulation stromal 
cell fate [129]. Thus, AUF1 could have a novel role to enhance the effect of IL-17 on 
immunosuppression. Similarly, IL-17a modified MSC have been reported to suppress 
proliferation of T cell in vitro via mechanisms such as inhibition of Th1 cytokines (IFN-γ, 
TNF-α, IL-10, and IL-2), enhance production of IL-6 and induction of regulatory T cells 
[130]. 
IL-6 priming of MSC infused into an acute model of CCl4 injury resulted in improved 
viability of isolated hepatocytes as well as a reduction in expression of pro-apoptotic markers 
such as BAX, Caspase-3 and LDH activities. This finding was not observed when MSC or 
IL-6 treatment were applied alone [131]. In addition, administration of IL-6 with MSC was 
found to enhance repair of liver injury in a mouse model of liver fibrosis with reductions in 
fibrosis, improvements in liver synthetic function, promote hepatocyte survival, and decrease 
apoptosis in fibrotic liver [131].   
 
Enhancing homing of MSC 
A study demonstrated that adhesion molecules such as ICAM and VCAM can be highly 
expressed on MSC following priming with a combination of IFN-γ, TNF-α and IL-1. This 
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upregulation of expression of ICAM and VCAM led to increased recruiting of MSC to 
vascular endothelium, this close contact of MSC with immune cells could enhance the 
immunosuppressive properties of MSC [132, 133]. Similarly, MSC pre-treated with IFN-γ, 
TNF-α can induced regulatory T cells more efficiently than non-treated MSC. Furthermore, 
MSC pre-incubated with IFN-γ, TNF-α induced secretion of CCR6 and therefore increase the 
adhesion of Th17 cells to MSC, resulting in promote the generation of regulatory T cells 
(FOXP3+ cell) from Th17 cells and consequently improve their immunosuppressive 
properties [134]. 
Priming with CXCL9 has also been shown to enhance adherence of MSC to endothelial cells 
as well as increase spreading of MSC on the endothelial cells as characterized by the 
extension of pseudopodia in multiple directions [135]. Further characterization of the 
beneficial effect of chemokines on MSC behaviour was reported in the same study using 
trans-well migration experiments, in which MSC migrated across endothelial layers in the 
presence of chemokines such as CXCL9, CXCL16, and CXCL20, and CXCL25. Of note no 
migration was observed in the presence of TNF-α alone.  
Genetic modification of MSC (Gene editing) 
Beside enrichment and priming MSC in vitro, transplantation of MSC after genetic correction 
or modification (gene editing) represents a powerful approach to use of MSC in regenerative 
medicine (Table 4). This section will review progress with genetic engineering approaches 
that have reported with MSC, including viral and non-viral manipulations. Viral transfection 
of MSC can be achieved with several approaches including lentivirus, adenovirus and 
retrovirus [136].   
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MSC have also been genetically modified to increase expression of CXCR4, thereby 
improving their homing to the injured liver and reducing liver damage [137]. Similarly, the 
same finding was reported in a rat model of lung injury, with increased expression of CXCR4 
on MSC resulting in enhanced hepatic migration and improvement of their 
immunomodulatory properties mediated by increased production of IL-10 and reduction in 
TNF-α. Notably, these findings suggest that overexpression of CXCR4 not only enhanced 
MSC homing but also increased their immunosuppressive effects [138].  
Further examination of the beneficial effects of genetic modified MSC was reported in a 
mouse model of liver fibrosis, following overexpression of insulin growth factor like-1 (IGF-
1) [139]. After systemic administration, IGF-1 modified MSC were able to significantly 
reduce the degree of fibrosis, likely through the down regulation of α-SMA, TGF-β and 
COL1A2 in animal treated with IGF-1 MSC when compare with animal treated with normal 
MSC [140]. Over-expression of HGF in MSC was also found to reduce liver fibrosis, 
seemingly mediated by a reduction in TFG-β, platelet-derived growth factor-bb (PDGF-bb), 
and metalloprotease-14 (MMP-14) [141]. HGF overexpressed MSC also act on hepatic 
stellate cells to reduce α-SMA and desmin expression, indicating that MSC that overexpress 
HGF decreased both the activation and number of hepatic stellate cells more greater level 
than MSC. This could have therapeutic effect to prevent diseases progression and foster liver 
restoration. 
Another reprogramming approach showed that over-expression of miR-27b in adipose tissue 
derived MSC resulted in reduction in a rat model of ischemic liver injury in rat with 
improvements in ALT, AST, TNF-α, and IL-6 as well as significance suppression in TGF-β 
  
23 
 
[142]. Moreover, these transfected cells were shown to have anti-fibrotic ability with 
suppression of MMP-2 and MMP-9 in liver tissue.  
Further study linked between the genetic modified MSC and their capacity to express 
endothelial cell (EC) markers with similar function. For example, silencing MMP-2 and 
MMP-14 with endothelial growth medium can induce the MSC differentiation into EC by 
enhance production of endothelial markers, such as PECAM and VE-cadherin. These 
markers were increase from 4 to 15% and from 4 to 30% after silencing MMP-2 and MMP-
12, respectively. This observation was in comparison with MSC that treated with endothelial 
growth medium only [143].  
In other work, the expression level of HO-1 was genetically modified in MSC and shown to 
have resistance to cell death under oxidative stress condition and enhance their anti-apoptotic 
properties [144]. Moreover, HO-1 overexpressed MSC have shown to have more surviving 
cells following exposure to H2O2 and hypoxia, indicating that HO-1 may shape the stress 
responsive and cytoprotective properties of MSC. Notably, in the murine model of 
myocardial infarction, overexpression of HO-1 resulted in diminished oxidative stress and 
apoptosis as well as an enhanced effect on angiogenesis. This was associated with a 2.1 fold 
up-regulation of VEGF levels compared to normal MSC [145].   
 
Conclusions and outlook 
MSC therapy is generally regarded as a safe and potentially relevant therapeutic strategy for 
patients with chronic liver disease, including ACLF, liver failure including cirrhosis due to 
alcohol, HBV, or HCV, and primary biliary cholangitis. However, in order for MSC therapy 
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to be established as a clinical therapeutics for those of liver diseases, further robust 
randomised clinical studies are required to increase the reliability of the clinical efficacy of 
MSC. In addition, further studies on optimal delivery route, sufficient number of MSC, and 
extension of survival of engrafted MSC are needed to enhance the efficacy of MSC therapy. 
However, several concerns still remain, including the low migration and fibrogenic potential 
of MSC, the optimal sources, and the risk of oncogenesis and viral transmission. Whilst, 
conventional unmanipulated MSC have constituted the mainstream of therapeutic clinical 
studies so far, there have been extensive efforts to enhance their efficacy, including 
enrichment and/or priming of MSC along with genetic engineering of cells. The main driver 
for these approaches is to enhance efficacy and/or organ homing although there is also often a 
need to create/protect intellectual property so as to generate a viable business model as well 
as balancing the additional costs and potential safety issues against enhanced efficacy.      
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Figure legends 
Figure 1. Modes of MSC-based therapy. 
Figure 2. Potential mechanisms of the MSC interactions with immune cells. 
Figure 3. Schematic diagram illustrating the future of using modified MSCs for tissue/organ 
regeneration. 
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Table1. Clinical studies of MSC in chronic liver diseases 
Study Year Design, 
F/U (month) 
Patient cohort Source of 
MSC 
Injection route Primary endpoint Main improvement 
Mohamadnejad 
et al. [94] 
2007 Case series 
12 
Decompensated liver 
cirrhosis (n=4) 
Autologous 
BM 
Peripheral vein Safety and feasibility Creatinine and MELD score  
Kharaziha et al. 
[92] 
2009 Cohort 
6 
Liver cirrhosis (n=8) Autologous 
BM 
Portal vein (n=6) 
Peripheral vein 
(n=2) 
Feasibility, safety, and 
efficacy (LFT and MELD 
score) 
Creatinine, prothrombin time and 
MELD score  
El-Ansary et al. 
[104] 
2010 Case control 
6 
Decompensated liver 
cirrhosis due to HCV or HBV 
(n=12) 
Autologous 
BM 
Intra-splenic (n=6) 
Peripheral vein 
(n=6) 
LFT and MELD score 
improvement 
Creatinine, prothrombin time, 
albumin, bilirubin and MELD 
score 
Amer et al. [97] 2011 Case control 
6 
Decompensated liver 
cirrhosis due to HCV (n=40) 
Autologous 
BM 
Intra-splenic (n=10) 
Intra-hepatic (n=10) 
Safety and short-term 
efficacy (LFT, MELD 
improvement) 
Ascites, peripheral oedema, 
albumin, MELD score, and Child-
Pugh score 
Peng et al. [99] 2011 Case control 
1, 48 
ACLF caused by HBV 
(n=158) 
Autologous 
BM 
Hepatic artery Improvement of MELD 
and LFT (short term) or 
Prothrombin time, albumin, 
bilirubin and MELD score 
  
47 
 
development of HCC and 
mortality (long term) 
El-Ansary et al. 
[98] 
2012 Case control 
6 
Decompensated liver 
cirrhosis due to HCV (n=25) 
Autologous 
BM 
Peripheral vein  Improvement of MELD 
and LFT 
Albumin and MELD score 
Shi et al. [100] 2012 Case control 
12 or 18 
ACLF associated HBV 
(n=43) 
Allogeneic 
UC 
Peripheral vein  LFT and MELD 
improvement, adverse 
events, and survival rates 
Albumin, prothrombin time, 
bilirubin, ALT, survival rates and 
MELD score 
Zhang et al [16] 2012 Case control 
12 
Decompensated liver 
cirrhosis due to HBV (n=45) 
Allogeneic 
UC 
Peripheral vein  Safety and efficacy (LFT 
and MELD) 
Albumin, bilirubin, MELD score 
and ascites 
Amin et al. [90] 2013 Cohort 
6 
Post-HCV 
(n=20) 
Autologous 
BM 
Intra-splenic Safety and efficacy Albumin, prothrombin time, 
bilirubin, AST, ALT and MELD 
score 
Mohamadnejad 
et al. [93] 
2013 RCT 
12 
Decompensated liver 
cirrhosis (n=25) 
 
Autologous 
BM 
Peripheral vein  Safety and efficacy None 
Wang et al. [15] 2013 Cohort UDCA-resistant PBC Allogeneic Peripheral vein  Safety and efficacy Alkaline phosphatase and γ-
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ACLF, acute-on-chronic liver failure; BM, bone marrow; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; LFT, liver function 
test; MELD, model for end-stage liver disease; PBC, primary biliary cholangitis; RCT, randomized controlled trial; UC, umbilical cord; UDCA, 
ursodeoxycholic acid 
12 (n=7) UC glutamyltransferase (GGT) levels 
Jang et al. [91] 2014 Cohort 
6 
Alcohol related liver cirrhosis 
(n=11) 
Autologous 
BM 
Hepatic artery Safety and efficacy MELD score and liver histology 
Salama et al. 
[95] 
2014 RCT 
6 
Post-HCV end-stage liver 
disease (n=40) 
Autologous 
BM 
Peripheral vein  Safety and efficacy MELD score and Child-Pugh 
score 
Wang et al. [96] 2014 Cohort 
12 
UDCA-resistant PBC (n=10) Allogeneic 
BM 
Peripheral vein  Safety and efficacy ALT, AST, GGT and IgM 
Suk et al. [101] 2016 RCT 
12 
Alcohol related liver cirrhosis 
(n=72) 
Autologous 
BM 
Hepatic artery Safety and efficacy Histologic fibrosis and Child-
Pugh score 
Lanthier et al. 
[103] 
2017 RCT 
1 
Decompensated alcoholic 
hepatitis (n=58) 
Autologous 
BM 
Hepatic artery Safety and efficacy None 
Lin et al. [102] 2017 RCT 
6 
ACLF associated HBV 
(n=110) 
Allogeneic 
BM 
Peripheral vein  Safety and efficacy Bilirubin, MELD score and 
survival rates 
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Table 2. Reported markers for selection and purification of MSC 
MSC 
Source 
Species 
Markers 
expressed 
Purification/ 
selection methods 
Experimental 
Models 
Target/ Mechanism Ref. 
BM Human 
CD271+ and 
CD56+ 
Cell Sorting In vitro 
• Increase clonogenic and proliferation potential. 
• Increase chondrocyte and pancreatic like cells 
differentiation. 
[105] 
BM Rat CD73+ Cell Sorting 
In vitro 
Lewis rats 
• Enhance self-renewal and differentiation. 
• Increase engraftment. 
[24] 
BM Human CD200+ 
Magnetic 
separation 
In vitro 
• Enhance regulation of bone resorption. 
• Inhibit osteoclast formation via inhibition of 
RANKL signaling pathway. 
[112] 
BM Human CD200+ Cell Sorting In vitro • Suppress TNF-α secretion in macrophage like [113] 
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cells (Immunosuppressive activity) 
UP, AT, 
and BM 
Human αSMA+ FACS In vitro 
• Improve MSC fate through regulation of 
YAP/TAZ activation. 
[146] 
PAM Human CD34+ FACS 
TAA (liver 
fibrosis model) 
• Reduce hepatic fibrosis and restore liver 
function by reduce collagen level and deactivate 
the hepatic stellate cells. 
[147] 
BM Human CD271+ 
Magnetic 
separation 
In vitro (model of 
wound healing) 
• Significant potential in wound healing [148] 
UCB Human CD 146+ FACS In vitro • Reduce MSC senescence. [107] 
BM Human ALDH FACS 
In vitro and in 
vivo (NOD/SCID 
mice) 
• Promote endothelial cell expansion. 
• Enhance recruitment of endogenous vascular 
cells in vivo by upregulation of lectin. 
[114] 
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SYN and 
BM 
Human 
LNGFR and 
THY-1 
FACS In vitro 
• Greater chondrogenic differentiation ability and 
colony forming potential than BM-MSC. 
[110] 
UC Human 
C362+ 
(Syndecan-2) 
FACS ALF 
• Improve immunomodulatory properties and 
clonogenicity. 
[119] 
BM Human STRO-1 FACS In vitro 
• Increase expression of cardiovascular relate 
cytokines. 
[116] 
Bone Marrow (BM), Umbilical cord (UC), Umbilical cord blood (UCB), Synovium (SYN), Placenta amnion membrane (PAM), Adipose tissue 
(AT), Umbilical perivascular (UP), Aldehyde dehydrogenase (ALDH). Stromal Precursor antigen-1 (Stro-1), Acute liver failure (ALF), Receptor 
activator of nuclear factor kappa-B ligand (RANKL) 
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Table 3. Reported factors and their effect in priming of MSC for tissue repair. 
MSC 
source 
Molecule 
name 
Time of 
treatment 
Biological Function Ref. 
Human 
BM 
Human 
AT 
IL-1β, IL-23, 
IL-6 
96 hours 
• Enhance secretion of TGF-β. 
• Reduce production of IL-4. 
• Exhibit significance multi-lineage. 
differentiation capacity. 
[121] 
Human 
BM 
 
IL-1 24 hours 
• Increase production of G-CSF. 
• Increase production of IL-10. 
[122] 
Human 
BM 
IFN-γ and 
TNF-α 
24 hours 
• Enhance osteogenic formation via 
expression of ALP. 
• Increase expression of bone matrix 
proteins. 
[124] 
Human 
UC 
IFN-γ, TGF-β, 
or multiple 
cytokine 
cocktail (IFN-
γ, TGF-β, and 
retinoic acid) 
72 hours 
• Multiple cytokines cocktails improve the 
immunomodulatory properties of MSC. 
• TGF-β treated MSC increased 
recruitment of MSC to the liver injury in-
vivo. 
[119] 
Mouse 
BM 
IFN-γ + TNF-
α with IL-17 
12 hours 
• Mediate liver injury through activation of 
iNOS. 
[125] 
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Human 
BM 
IL-17 
24, 48, 
and 120 
hours. 
• Induction regulatory T cells. 
• Inhibition of Th1 cytokines. 
• Enhance production of IL-6. 
[126] 
Mouse 
BM 
IL-6 24 hours 
• Improve viability of hepatocytes treated 
with CCL4. 
• Decreased expression of pro-apoptotic 
markers (BAX, caspase-3, and LDH). 
• Reduced liver fibrosis in vivo. 
[127] 
Mouse 
BM 
IFN-γ or (TNF-
α and IL-1) 
Not sure 
• Increase upregulation of ICAM and 
VCAM. 
[128] 
Mouse 
BM 
(IFN-γ + TNF-
α + IL-1α) or 
(IL-1β + IFN-
γ) 
24 hours 
• Increase ability of MSC to inhibit T cell 
proliferations. 
• Enhance secretion of chemokines such as 
CXCL-9 and CXCL-10. 
[40] 
Mouse 
BM 
CXCL9 
30 
minutes 
• Ameliorate the adhesion of MSC to 
murine endothelial cells. 
[130] 
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Table 4. Genetically modified MSC 
MSC 
source 
Example of 
associated 
genes 
Condition 
Viral 
vector 
Representative 
biological activities 
Ref. 
Mouse 
BM 
IGF-1 
overexpression 
Liver 
cirrhosis 
Adenovirus 
• Ameliorate liver fibrosis 
by significant reduction 
in α-SMA, collagen 
deposition, and TGF-β1. 
[140] 
Mouse 
BM 
Let-7a       
Knockdown 
IBD and 
GVHD 
siRNA 
• Significant improvement 
in both models, by 
suppress T cell 
proliferation (decreased 
in CD3+), increase 
MCP-1 secretion, and 
enhancing expression of 
Fasl/Fas. 
[149] 
Human 
BM 
CXCR5 
overexpression 
CHS Lentiviral 
• Increase migration and 
engraftment of MSC to 
the site of injury. 
• Enhance 
immunomodulatory 
effects of MSC in vivo 
through inhibit of T cell 
[150] 
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proliferation and supress 
production of IFN-γ and 
IL-17. 
Human 
BM 
CXCR4 
overexpression 
ALF Lentiviral 
• Enhance migration and 
improve liver 
regeneration. 
[144] 
Rat 
BM 
CXCR4 
overexpression 
Lung 
injury 
Lentiviral 
• Improve migration and 
suppress inflammation 
of lung tissue by 
upregulation of IL-10 
and downregulation of 
TNF-α. 
[145] 
Rat AT 
miR-27b 
overexpression 
Partial 
hepatectomy 
Micro 
RNA 
• Enhance liver 
regeneration through 
reduction in ALT, TNF-
α, and IL-6 in serum. 
• Reduce expression of 
TGF-β, MMP2, and 
MMP9. 
[142] 
Rat 
MB 
CAMKK1             
over 
expression 
AMI siRNA 
• Reduce scar formation 
and improve cardiac 
function in vivo. 
[151] 
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Porcine 
AT 
MMP-2 and 
MMP-14 
knockdown 
In-vitro siRNA 
• Enhance differentiation 
of MSC into endothelia 
cells by production of 
PECAM and V-
cadherin. 
• Increase the formation 
of capillary like cells 
and Sc-LDL uptake. 
[143] 
Human 
BM 
HO-1   
overexpression 
In-vitro Adenovirus 
• Enhance MSC survival 
and resistant to 
oxidative stress. 
• Enhanced anti-apoptotic 
and anti-oxidative 
capabilities of MSC 
[144] 
Rat 
BM 
HO-1   
overexpression 
MI Plasmid 
• Enhanced anti-apoptotic 
and anti-oxidative 
properties and improved 
angiogenesis level. 
[145] 
Human 
BM 
HGF     
overexpression 
Liver 
Fibrosis 
(MDN 
model) 
Adenovirus 
• Promote liver function 
and reduce liver fibrosis 
via significant reduction 
in TGF-β and PDGF-bb. 
[141] 
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Mouse 
BM 
COUP-TF1 
knockdown 
Streptozocin-
induced 
diabetic mice 
siRNA 
• Increase ability of BM-
MSC to differentiate 
into IPCs. 
[152] 
Rat 
BM 
Aqp1 
overexpression 
Tibia fracture 
Model 
Lentiviral 
• Enhance MSC migration 
in vitro and in vivo 
through modulation 
expression of FAK and 
β-catenin. 
[153] 
Insulin growth factor like-1 (IGF-1), Inflammatory bowel disease (IBD), graft versus host 
disease (GVHD), Contact hypersensitivity (CHS), acute liver failure (ALF), amniotic fluid 
(AF), calcium/calmodulin-dependent protein kinase kinase-1 (CAMKK1), acute myocardial 
infarction (AMI), matrix metalloproteinases (MMPs), heme oxygenase-1 (HO-1), hepatocyte 
growth factor (HGF), Di-methylnitrosamine (DMN), platelet-derived growth factor-bb 
(PDGF-bb), chicken ovalbumin upstream promoter transcriptional factor I (COUP-TFI), 
Insulin producing cells (IPCs), Aquaporin 1 (Aqp1), focal adhesion kinase (FAK). 
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